Department of Radiation Oncology, Columbia University Irving Medical Center, New York, New York, USA.
Division of Neuro-Oncology, Columbia University Irving Medical Center, New York, New York , USA.
Neuro Oncol. 2024 Mar 4;26(12 Suppl 2):S66-S75. doi: 10.1093/neuonc/noad184.
The clinical efficacy and relative tolerability of adverse effects of immune checkpoint immunotherapy have led to its increasingly routine use in the management of multiple advanced solid malignancies. Radiation therapy (RT) is well-known to have both local and distant immunomodulatory effects, which has led to extensive investigation into the synergism of these 2 therapies. While the central nervous system (CNS) has historically been thought to be a sanctuary site, well-protected by the blood-brain barrier from the effects of immunotherapy, over the last several years studies have shown the benefits of these drugs, particularly in metastatic disease involving the CNS. This review explores current progress and the future of combination therapy with immune checkpoint inhibitors and RT.
免疫检查点免疫疗法的临床疗效和相对耐受性使其在多种晚期实体恶性肿瘤的治疗中得到越来越常规的应用。众所周知,放射治疗(RT)具有局部和远处的免疫调节作用,这促使人们广泛研究这两种治疗方法的协同作用。虽然中枢神经系统(CNS)在过去被认为是一个避难所,由于血脑屏障的存在而免受免疫治疗的影响,但在过去几年的研究表明,这些药物,特别是在涉及中枢神经系统的转移性疾病中,具有疗效。本文探讨了免疫检查点抑制剂联合 RT 治疗的当前进展和未来前景。